Dermatologic Therapy最新文献

{"title":"Efficacy and Safety of Low-Dose Isotretinoin, Spironolactone, and Diammonium Glycyrrhizinate for Acne in Women With Hyperandrogenism: A Randomized Controlled Trial","authors":"Xinyi Jing, Junlan Yang, Shuyao He, Jianwen Ren","doi":"10.1155/dth/4066937","DOIUrl":"https://doi.org/10.1155/dth/4066937","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The prevalence of acne among adult women is increasing, and androgens play an important role in its pathogenesis. This study aimed to evaluate the short-term efficacy and safety of low-dose isotretinoin combined with spironolactone, diammonium glycyrrhizinate, or both in the treatment of women with moderate-to-severe acne and hyperandrogenism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a single-center, randomized, open-label, assessor-blinded clinical trial. The study protocol was approved by the hospital’s Medical Ethics Committee (Approval No. 2023-[054]) and was retrospectively registered with the Chinese Clinical Trial Registry (ChiCTR2500099023) on March 17, 2025, after completion of participant enrollment. A total of 112 participants were randomly assigned to four groups (<i>n</i> = 28 per group): Group A (isotretinoin 0.2 mg/kg/day), Group B (isotretinoin 0.2 mg/kg/day plus spironolactone 40 mg/day), Group C (isotretinoin 0.2 mg/kg/day plus diammonium glycyrrhizinate 150 mg/day), and Group D (triple therapy). Treatment duration was 8 weeks. The prespecified primary efficacy endpoint was the lesion clearance rate at Week 8, defined as the percentage reduction in total lesion count from baseline. Secondary outcomes included changes in lesion counts, Global Acne Grading System (GAGS) scores, VISIA red area percentiles, quality of life and psychological measures (Dermatology Life Quality Index [DLQI], Generalized Anxiety Disorder-7 [GAD-7], and Patient Health Questionnaire-9 [PHQ-9]), and serum hormone levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All treatment regimens were associated with clinical improvement after 8 weeks. The triple therapy group (Group D) achieved the greatest reduction in total lesion count, with a mean lesion clearance rate of 90.59% (95% CI, 88.25–92.92), compared with 73.94% (95% CI, 67.70–80.17) in Group A, 80.10% (95% CI, 75.06–85.14) in Group B, and 81.70% (95% CI, 77.52–85.88) in Group C. Reductions in lesion counts and GAGS scores were observed across all groups, and VISIA red area percentiles increased, indicating improvement in facial erythema-related metrics. Quality of life and psychological measures improved in all treatment arms. Exploratory analyses showed changes in selected serum hormone parameters during treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this short-term, single-center, open-label, assessor-blinded trial, low-dose isotretinoin combined with spironolactone and diammonium glycyrrhizinate demonstrated greater short-term clinical imp","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4066937","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Role of Baseline Creatine Kinase Measurement Before Initiating Oral Isotretinoin in Acne Vulgaris Patients: Insights From a Retrospective Cohort of 1256 Individuals","authors":"Neslihan Demirel Öğüt,&nbsp;Saadet Miray Ayyıldız,&nbsp;Sema Koç Yıldırım,&nbsp;Ece Erbağcı,&nbsp;Simge Ünal Işık,&nbsp;Ece Gökyayla","doi":"10.1155/dth/2680904","DOIUrl":"https://doi.org/10.1155/dth/2680904","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction and Background</h3>\u0000 \u0000 <p>Isotretinoin is a highly effective treatment for severe acne vulgaris, but it may cause musculoskeletal side effects, including elevations in serum creatine kinase (CK) levels. Current guidelines do not mention routine CK monitoring unless musculoskeletal symptoms are present. This study aimed to evaluate temporal changes in CK levels during isotretinoin therapy to clarify their clinical relevance and inform safer, evidence-based monitoring strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>This retrospective observational cohort study included patients treated with oral isotretinoin for acne vulgaris between January 2022 and July 2024. Data were extracted from medical records and included demographics, cumulative isotretinoin dose, and laboratory values (CK, AST, and ALT) assessed at baseline and at the 1st, 2nd, 4th, and 6th months of therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1256 patients were analyzed (mean age 19.69 ± 3.9 years); 75.1% were female. The median baseline CK level was 73 U/L (range: 15–5505), and 6.5% (<i>n</i> = 82) had CK levels ≥ 200 U/L before treatment. By Month 6 (<i>n</i> = 452), the mean cumulative isotretinoin dose was 4928 ± 324.2 mg, and median CK was 70 U/L (range: 15–4267). During follow-up, 26 patients showed both CK ≥ 200 U/L and ≥ 5-fold increases from baseline. However, follow-up CK levels did not significantly differ from baseline. CK changes were moderately correlated across time points and weakly to moderately correlated with ALT and AST changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although isotretinoin did not cause a significant overall increase in CK levels, marked individual variability and occasional elevations were observed. Baseline CK assessment may facilitate interpretation of subsequent changes, particularly in patients with muscle-related symptoms. Moderate correlations between CK and AST suggest a possible muscular contribution to some transaminase elevations. Routine CK monitoring is unnecessary; however, individualized evaluation based on baseline values may improve patient safety. Prospective studies are needed to refine monitoring strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2680904","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147585302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Macrophages in Atopic Dermatitis","authors":"Xue Chen,&nbsp;Jianxin Shi,&nbsp;Hao Wu,&nbsp;Hongmin Li","doi":"10.1155/dth/6142669","DOIUrl":"https://doi.org/10.1155/dth/6142669","url":null,"abstract":"<p>Atopic dermatitis (AD) is an allergic disease characterized by chronic inflammation and immune dysregulation, with pathogenesis involving a complex network of immune responses. Macrophages, as central components of the immune system, play diverse roles in AD: acting as promoters of inflammatory responses and potential facilitators of repair. This article reviews the functions of macrophages in AD, their molecular mechanisms, and interactions with other immune cells and explores future research directions and therapeutic strategies from the macrophage perspective.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6142669","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147579852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitors vs. Targeted Therapy in BRAF-Mutated Melanoma: A Systematic Review","authors":"Madeline Guy,&nbsp;Omar El-Kholy,&nbsp;Ahmed Adham R. Elsayed,&nbsp;Marc D. Basson","doi":"10.1155/dth/9105971","DOIUrl":"https://doi.org/10.1155/dth/9105971","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Skin cancer is a common malignancy. Although melanoma represents only 3% of cases, it causes 65% skin cancer–related deaths, with incidence rising worldwide. Melanoma’s severity stems from alterations in the MAPK pathway, triggered by BRAF mutations in 50% of melanoma cases. Immune checkpoint inhibitors (CPIs) and targeted therapy (TT) are therapeutic advancements that enhance survival outcomes in melanoma. However, the relative benefits of these therapies as first-line treatment remain unclear. This systematic review assesses patient outcomes with CPI versus TT to determine optimal first-line therapy for BRAF-mutated melanoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The search consisted of four databases (Cochrane, PubMed, Scopus, and WOS) from Inception to May 2025, following the PRISMA guideline. STROBE and CARE tools assessed reporting quality for observational studies and case reports, respectively. Therapies were categorized as CPI (anti-CTLA-4: e.g., ipilimumab; anti-PD-1: e.g., pembrolizumab; dual inhibition anti-CTLA-4/anti-PD-1 immunotherapy: e.g., ipilimumab/nivolumab) or TT (BRAFi monotherapy: e.g., vemurafenib; BRAFi/MEKi combination: e.g., dabrafenib/trametinib). This categorization allowed clinical practice and guideline-aligned comparative analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirteen studies, with over 5150 patients, directly compared CPI (anti-CTLA-4, anti-PD-1, or both) and TT (BRAFi, MEKi, or both). While TT demonstrated superior ORR, CPI, especially anti-PD-1 or dual immune blockade immunotherapy, consistently outperformed TT in long-term metrics such as OS. Weighted quantitative analysis demonstrates that CPI therapy is associated with 47%, 53%, and 48% reduction in 1-year, 2-year, and overall mortality risk compared to TT. CPI is also associated with less frequent but more severe adverse events, specifically irAEs (e.g., hepatitis and colitis).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Immune checkpoint inhibitors and TT exhibit different advantages in the treatment of BRAF-mutated melanoma. Current evidence identifies immune checkpoint inhibitors as the preferred treatment for BRAF-mutated melanoma due to a significantly increased overall survival and more sustainable responses compared to TT, although TT remains favored in immunocompromised populations as well as those with poor prognostic factors requiring rapid response.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9105971","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147614913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucocorticoid Receptor Level as an Immunohistochemical Biomarker for Identification and Severity Assessment of Psoriasis and Its Association With Psoriasis Patients Complicated by Obesity and Hyperuricemia","authors":"Yuping Zhang,&nbsp;Xiji Lu,&nbsp;Fengjiao Meng,&nbsp;Chen Li","doi":"10.1155/dth/6715205","DOIUrl":"https://doi.org/10.1155/dth/6715205","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Psoriasis is a common, chronic epidermal hyperplastic and inflammatory skin disease. Studies have shown that the reduction of skin-derived glucocorticoids (GC) may be one of the pathogenic factors of psoriasis. However, the clinical significance of the glucocorticoid receptor (GR) in patients with psoriasis remains unclear. This study aims to investigate the immunohistochemical expression of GR in psoriatic lesional tissues and its quantitative correlation with psoriasis severity, as well as to clarify the direction of this association (positive or negative).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Skin tissue and corresponding patient information were collected from 15 patients with chronic eczema (CE), 15 patients with lichen planus (LP), 26 patients with psoriasis, and 15 healthy adults. The skin tissue was embedded in paraffin and sectioned, followed by immunohistochemical staining using a GR antibody. The clinicopathological data were then correlated with the staining results. Disease severity was assessed using the Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator’s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI) scoring systems.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We compared GR levels in skin tissues among healthy adults and patients with psoriasis, CE, and LP. Compared with normal skin tissues, GR levels were reduced in lesional skin of both CE and LP, with an even more pronounced decrease observed in psoriasis tissues (<i>p</i> &lt; 0.01). Among the three psoriasis subtypes (ordinary psoriasis [psoriasis], pustular psoriasis [PP], and psoriatic arthritis [PA]), GR expression was the highest in the lesional skin of PA patients, exceeding that found in psoriasis patients, while expression was lower in PP lesions (<i>p</i> &lt; 0.01). Strong positive correlation was found between PASI and BSA (<i>r</i> = 0.8). In comorbidity analysis, psoriasis with obesity (PO) showed increased GR levels (<i>p</i> &lt; 0.01), whereas psoriasis associated with hyperuricemia (PH) did not, confirming GR as a reliable diagnostic marker for psoriasis despite comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>GR level shows promise as an immunohistochemical biomarker for identifying psoriasis and assessing its severity. While comorbidities like obesity may affect its utility as a diagnostic marker, in the case of hyperuricemia, GR levels remain a reliable indicator.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6715205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147567353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Systemic Inflammatory Biomarkers Between Psoriasis and Depression: Mediation Analysis in a Large U.S. Population-Based Survey","authors":"Yuhao Chen,&nbsp;Yunxuan Zhang,&nbsp;Xuhao Huang,&nbsp;Xiaoyan Luo,&nbsp;Hua Wang","doi":"10.1155/dth/9878608","DOIUrl":"https://doi.org/10.1155/dth/9878608","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis is a chronic relapsing systemic inflammatory disease with a high prevalence of psychiatric comorbidities, especially depression. However, the precise role of inflammation in the relationship between psoriasis and depression remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>We explored the association among psoriasis, systemic inflammatory biomarkers, and depression in a large, ethnically diverse sample from the 2009–2014 National Health and Nutrition Examination Survey (NHANES) data. Psoriasis was estimated by the questionnaire. Depression was evaluated using the 9-item Patient Health Questionnaire (PHQ-9). Systemic inflammation response index (SIRI) and neutrophil-to-lymphocyte ratio (NLR) were determined using the examination data. Meanwhile, multivariable logistic and linear regression analyses explored the relationship between psoriasis, systemic inflammatory markers, and depression. On the basis of restricted cubic spline (RCS) regression, we further explored the potential linear relationship between systemic inflammatory biomarkers and depression. Finally, a mediation model was established to explain the intermediary role of systemic inflammatory biomarkers in this relationship.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>Among the 12,734 participants in this study, 1172 participants had a depression score ≥ 10. After full adjustment, psoriasis was positively associated with depression and systemic inflammatory markers (for depression, OR [95% CI]: 2.000 [1.500, 2.668]; for LnSIRI, <i>β</i> [95% CI]: 0.091 [0.033, 0.150]; for LnNLR, <i>β</i> [95% CI]: 0.053 [0.006, 0.099]). Meanwhile, systemic inflammatory marker levels were linearly associated with depression (LnSIRI: Pnon-linear = 0.696; LnNLR: Pnon-linear = 0.921). Further mediation analysis indicated that SIRI and NLR mediated a marginal portion of the potential effects of psoriasis on depression, with proportions of 1.64% and 2.00%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Psoriasis is a risk factor for depression. Blood-based systemic inflammatory biomarkers are an easily accessible and cost-effective tool for identifying psoriasis and partially mediating the association between psoriasis and depression. It may provide important insights into guiding anti-inflammatory treatment strategies to prevent depression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9878608","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147567037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Causal Association Between Atopic Dermatitis and Chronic Obstructive Pulmonary Disease in European and East Asian Populations","authors":"Guo Zhen Fan,&nbsp;Jian Xiang Gao,&nbsp;Li Xin Hu,&nbsp;Zheng Hai Qu,&nbsp;Yin Bo Liu","doi":"10.1155/dth/1530943","DOIUrl":"https://doi.org/10.1155/dth/1530943","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This research aimed to investigate the causal relationship between atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD) among European and East Asian populations through bidirectional Mendelian randomization (MR) analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study utilized aggregated data from large-scale population genome-wide association studies, employed the inverse-variance weighted (IVW) method as the primary analytical approach for MR analysis, and conducted sensitivity analyses to evaluate the robustness of the MR analysis results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The IVW analysis results suggested a statistically significant positive causal effect of AD on COPD in both European and East Asian populations, while COPD did not have a statistically significant causal effect on AD in these populations. The results of Cochran’s Q statistic, MR-Egger intercept, and MR-PRESSO tests suggested no significant heterogeneity or potential horizontal pleiotropy. The leave-one-out analysis revealed that the causal effect was not influenced by any individual SNP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among European and East Asian populations, AD may increase the risk of developing COPD, and there is no evidence indicating that COPD has a causal impact on the risk of AD onset. Therefore, screening for COPD in AD patients should be enhanced.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1530943","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147566573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Exosome-Based Dermatological and Pharmacological Applications: Analysis of Emerging Topics and Therapeutic Opportunities Using Mapping and Visual Examination","authors":"Ahmad Assiri","doi":"10.1155/dth/1210451","DOIUrl":"https://doi.org/10.1155/dth/1210451","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Exosomes, small extracellular vesicles, are increasingly pivotal in dermatological research for their therapeutic potential in skin-related applications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study provides the first clinically oriented, time-resolved bibliometric mapping of exosome research in dermatology, integrating thematic evolution, pharmacological relevance, and translational implications from 2001 to 2025. Methods: The study analyzed 810 English-language original articles from 378 journals, sourced via a structured Scopus search on February 5, 2025, using MeSH-derived keywords, with analysis conducted using Bibliometrix (R version 4.2.1) and VOSviewer (version 1.6.19) to assess citation patterns, keyword dynamics, and collaborative networks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Core journals like International Journal of Molecular Sciences (20 articles) and scholars like Wang, Y. (H-index = 22) drive the field, with trends toward stem cell–derived exosomes and hydrogels. The field shows a 19.9% annual growth rate and 70.23 citations per document, with exosomes dominating (502 occurrences), followed by wound healing (112), melanoma (56), and angiogenesis (53). Research evolved from wound healing (6 occurrences, 2001–2020) to melanoma and diabetic wound healing (7 each, 2021–2023), and regenerative themes like extracellular vesicles (4, 2024–2025). China leads in output (398 publications) and citations (20,933), while the United States excels in collaboration (TLS = 70).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Exosomes are central to dermatological innovation, necessitating enhanced global and interdisciplinary collaboration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1210451","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147566572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis B Reactivation in Biologic-Treated Moderate-to-Severe Psoriasis: A Real-World Cohort Study With 534 Patient-Years of Follow-Up","authors":"Neslihan Demirel Öğüt,&nbsp;Muhammed Numan Sarıtaş,&nbsp;Merve Duğan,&nbsp;Ece Erbağcı,&nbsp;Sema Koç Yıldırım,&nbsp;Simge Ünal Işık,&nbsp;Ece Gökyayla","doi":"10.1155/dth/5653261","DOIUrl":"https://doi.org/10.1155/dth/5653261","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis vulgaris is a chronic immune-mediated inflammatory disease frequently requiring long-term biologic therapy. Although biologics targeting TNF-α and interleukin pathways have revolutionized disease management, they may disrupt antiviral immune surveillance and trigger hepatitis B virus (HBV) reactivation in individuals with prior HBV exposure. Data on the long-term safety of newer agents—particularly IL-17 and IL-23 inhibitors—in patients with prior HBV exposure remain limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate longitudinal changes in HBV serological and virological markers and determine the frequency of HBV reactivation among patients with psoriasis vulgaris receiving biologic therapies in routine clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective, single-center study included adult patients treated with biologics between December 2019 and January 2025. HBV serology (HBsAg, anti-HBs, and anti-HBc) and HBV-DNA were assessed at baseline and every 6 months, with 3-monthly monitoring for anti-HBc–positive patients from electronic hospital records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 345 biologic treatment episodes in 311 patients, corresponding to 534.3 patient-years of exposure, were analyzed. Biologic therapies included secukinumab (33%), risankizumab (24.6%), guselkumab (17.7%), ixekizumab (15.4%), adalimumab (4.1%), certolizumab pegol (2.9%), and ustekinumab (1.7%). Anti-HBc positivity was identified in 42 treatment episodes (12.2%), of whom 93% received antiviral prophylaxis. Four HBV reactivation events (9.5%) were observed—two during ixekizumab, one during secukinumab, and one during risankizumab therapy—without progression to clinical hepatitis. The incidence of HBV reactivation among anti-HBc–positive patients was 5.42 per 100 patient-years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this real-world cohort, HBV reactivation occurred in a clinically meaningful proportion of patients with prior HBV exposure (9.5%), presenting exclusively virologic or serologic reactivation without clinical hepatitis despite widespread antiviral prophylaxis. These findings underscore the need for individualized risk assessment and continuous virologic monitoring during biologic therapy and highlight the importance of further prospective studies to inform future clinical guidelines.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5653261","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147566169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Jmoon Transdermal Collagen Light Beauty Device for Facial Rejuvenation: A 12-Week Exploratory Clinical Study","authors":"Linting Huang,&nbsp;Ke Liu,&nbsp;Lanjun Liu,&nbsp;Qiuping Fei,&nbsp;Yali Yang,&nbsp;Yue Han,&nbsp;Fang Zhang,&nbsp;Rui Zheng,&nbsp;Xiaoxi Lin,&nbsp;Wei Fang","doi":"10.1155/dth/8965155","DOIUrl":"https://doi.org/10.1155/dth/8965155","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Facial photoaging affects the health and quality of life of middle-aged and elderly individuals. While energy-based aesthetic technologies help delay aging, clinical evidence for home-use devices remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the clinical efficacy and safety of the Jmoon Transdermal Collagen Light Beauty Device for facial rejuvenation over a 12-week period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty-six healthy female volunteers with mild-to-moderate facial aging were recruited. The device’s effects on facial rejuvenation were assessed using VISIA imaging, PRIMOS-CR 3D image analysis, Wood’s lamp, multifunctional skin testing, and skin ultrasound.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-four participants completed the study. After 12 weeks of continuous device use, significant improvements were observed in skin hydration (33.7% increase), firmness (21.7% increase), elasticity (22.0% increase), skin tone (39.9% increase), and brightness (8.0% increase) (all <i>p</i> &lt; 0.0001). Sebum (49.6% reduction), melanin (22.0% reduction), and erythema (17.0% reduction) levels also decreased significantly (all <i>p</i> &lt; 0.0001). PRIMOS-CR 3D imaging showed significant reductions in wrinkle area, length, volume, and number (all <i>p</i> &lt; 0.05). Skin ultrasound revealed a significant increase in dermal thickness (<i>p</i> &lt; 0.0001). The overall average pain score was 1.9 ± 1.7 based on a 0–10 Visual Analog Scale, with no severe adverse effects such as erythema, blisters, or pigmentation. Satisfaction scores indicated that the satisfaction rate reached 94.1%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Jmoon Transdermal Collagen Light Beauty Device significantly improved skin hydration, oil control, whitening, firmness, elasticity, and dermal thickness, while reducing erythema and wrinkles. It demonstrated a favorable safety profile and high user satisfaction in this exploratory study.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2400090845</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8965155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}